The CRISPR FORUM: CRISPR - Drug discovery tool or therapeutic revolution?

Location: Dublin, Ireland



CO-CHAIRS: Professor Eric Hendrickson (University of Minnesota Medical School) and Dr Jon Moore (Horizon Discovery)


The discovery of the RNA programmable nucleases Cas9 and Cpf1 has greatly facilitated genome editing. The impact of CRISPR technology has been universal, bringing drug discovery to an era of whole genome knockout screens and widely distributed multiplexed in vivo gene editing experiments, as well as moving into the clinic to join ZFN and TALEN powered therapies progressing towards registration.

This unique meeting, being held in Dublin on 17-18 October, will bring leaders in the field together with a wide academic and commercial audience, to explore the new horizons in drug development and therapeutics brought by advancements in CRISPR technology.

What makes this meeting different:

  • A substantial proportion of the oral programme will be given over to talks selected from submitted abstracts to discuss innovative ideas.

  • A focus on closing the gap between new developments in CRISPR technology and application in life sciences

This event will be held in association with The Pathologist, media partner to The CRISPR Forum 2017. 

The Pathologist

Join us to learn about the next wave of CRISPR innovation.




Kilian Huber, Nuffield Department of Medicine, University of Oxford

Andrew Bassett, Wellcome Trust Sanger Institute

Patrick Harrison, University College Cork

Tilmann Buerckstuemmer, Horizon Discovery

Benjamin P Kleinstiver, Massachusetts General Hospital

Linda Popplewell, Royal Holloway, University of London



Tuesday 17 October

Keynote Presentation: CRISPR/Cas9 as a new chapter in the history of gene editing

Eric Hendrickson, University of Minnesota Medical School: Mechanism of gene editing

Therapeutic applications of CRISPR/Cas9

Linda Popplewell, Royal Holloway, University of London: Towards therapy of Duchenne Muscular Dystrophy

Patrick Harrison, University College Cork: Cystic Fibrosis

Tom Henley, Horizon Discovery: TBC

Improvements in CRISPR Technology

Anna Cereseto, University of Trento: Hit and go Cas9 delivered through a lentiviral based self-limiting circuit

Ben Kleinstiver, Massachusetts General Hospital: Hi fidelity Cas9


Wednesday 18 October

Target ID & validation

Carlos le Sage, Horizon Discovery: Getting the best deal - Compare and contrast CRISPR KO, CRISPRi and CRISPRa

Jon Moore, Horizon Discovery: Synthetic lethal target ID

Emma Shanks, The Beatson Institute: Arrayed CRISPR screens

Yaron Galanty, University of Cambridge: Whole genome CRISPR screens

Tilmann Buerkstuemmer, Horizon Discovery: Rapid generation of conditional mutants with CRISPR technology

Applications: The CRISPR revolution in practice

Andrew Bassett, Wellcome Trust Sanger Institute: Using CRISPR to understand miRNA target site regulation

Kilian Huber, Structural Genomics Consortium Oxford University: Target ID via proteomics and CRISPR/Cas9

Closing remarks

Jon Moore, Horizon Discovery



Please complete the call for presentations form.

Areas of particular interest include:

  • Technical advancements

  • CRISPR Drug Discovery and development

  • Cell Therapy



Please be aware, registration does not include accommodation. Below are two nearby hotels within a five-minute walk of the conference venue:

Jurys Inn Christchurch

Paramount Hotel



If you are involved in arranging similar educational meetings and conferences, and looking for support, please do let us know by emailing


Register  Submit Abstract  

All news, events & press
Back to top